Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma

Clin Lung Cancer. 2017 May;18(3):e215-e217. doi: 10.1016/j.cllc.2017.01.003. Epub 2017 Jan 11.
No abstract available

Keywords: EGFR; NSCLC; Next generation sequencing; Tyrosine kinase inhibitors; Uncommon mutation.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics
  • Aged
  • DNA Mutational Analysis
  • Drug Resistance, Neoplasm / genetics
  • Drug-Related Side Effects and Adverse Reactions / diagnosis*
  • Dyspnea / diagnosis*
  • Dyspnea / etiology
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics
  • Exons / genetics
  • Gefitinib
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Male
  • Mutation / genetics
  • Pleural Effusion / diagnosis*
  • Pleural Effusion / etiology
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Quinazolines / adverse effects
  • Quinazolines / therapeutic use*

Substances

  • Protein Kinase Inhibitors
  • Quinazolines
  • EGFR protein, human
  • ErbB Receptors
  • Gefitinib